• TOT BioPharm posted a net loss of RMB 59 million for the six months ended June 30, swinging from profit.
• Revenue fell 49.7% to RMB 246 million, reflecting a sharp drop in self-developed product sales on industry competition.
• CDMO revenue more than doubled to RMB 199 million, while self-developed products revenue plunged 88.6% to RMB 45 million.
• Gross profit dropped 85.1% to RMB 53 million, pushing gross margin down to 21.4%.
• Order backlog climbed 95.5% to RMB 391 million; CMC projects rose to 134, including five Phase III projects and one commercial project.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TOT BIOPHARM International Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260821-12294673), on August 21, 2026, and is solely responsible for the information contained therein.